STAT3: A critical transcription activator in angiogenesis

被引:240
作者
Chen, Zhong [1 ,2 ,3 ]
Han, Zhong Chao [1 ,2 ,3 ]
机构
[1] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin 30020, Peoples R China
[2] Chinese Acad Med Sci, Hosp Blood Dis, Tianjin 30020, Peoples R China
[3] Peking Union Med Coll, Tianjin 30020, Peoples R China
关键词
STAT3; VEGF; interleukin-6; angiogenesis; transcription factors;
D O I
10.1002/med.20101
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Angiogenesis, the formation of new blood vessels from the pre-existing vasculature, is a complex multistage process regulated by a number of signal transduction pathways. Accumulating evidence suggests that signal transducer and activator of transcription (STATs), mainly STAT3, play an important role in angiogenesis under both physiological and pathological conditions in addition to cell survival, proliferation, differentiation, and oncogenesis. STAT3, as a critical multifunctional mediator, regulates many aspects of angiogenesis at the transcriptional level. This review will highlight the pivotal role of STAT3 in well-studied tumorous angiogenesis and cardiac angiogenesis, and summarize various potential mechanisms utilized by STAT3 to regulate the transcriptional activation of VEGF. (c) 2007 Wiley Periodicals, Inc.
引用
收藏
页码:185 / 200
页数:16
相关论文
共 113 条
[1]   Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma [J].
Acs, G ;
Zhang, PJ ;
Rebbeck, TR ;
Acs, P ;
Verma, A .
CANCER, 2002, 95 (05) :969-981
[2]   Prognostic significance of erythropoietin expression in human endometrial carcinoma [J].
Acs, G ;
Xu, XW ;
Chu, C ;
Acs, P ;
Verma, A .
CANCER, 2004, 100 (11) :2376-2386
[3]   Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas [J].
Adachi, Yasuo ;
Aoki, Chieko ;
Yoshio-Hoshino, Naoko ;
Takayama, Koichi ;
Curiel, David T. ;
Nishimoto, Norihiro .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (06) :1303-1311
[4]   VEGF differentially activates STAT3 in microvascular endothelial cells [J].
Bartoli, M ;
Platt, DH ;
Lemtalsi, T ;
Gu, XL ;
Brooks, SE ;
Marrero, MB ;
Caldwell, RB .
FASEB JOURNAL, 2003, 17 (09) :1562-+
[5]  
Benckert C, 2003, CANCER RES, V63, P1083
[6]   Expression of leptin receptor isoforms in rat brain microvessels [J].
Bjorbæk, C ;
Elmquist, JK ;
Michl, P ;
Ahima, RS ;
van Bueren, A ;
McCall, AL ;
Flier, JS .
ENDOCRINOLOGY, 1998, 139 (08) :3485-3491
[7]   Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis [J].
Bowman, T ;
Broome, MA ;
Sinibaldi, D ;
Wharton, W ;
Pledger, WJ ;
Sedivy, JM ;
Irby, R ;
Yeatman, T ;
Courtneidge, SA ;
Jove, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) :7319-7324
[8]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[9]   Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects [J].
Burdelya, L ;
Kujawski, M ;
Niu, GL ;
Zhong, B ;
Wang, TH ;
Zhang, SM ;
Kortylewski, A ;
Shain, K ;
Kay, H ;
Djeu, J ;
Dalton, W ;
Pardoll, D ;
Wei, S ;
Yu, H .
JOURNAL OF IMMUNOLOGY, 2005, 174 (07) :3925-3931
[10]   KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway [J].
Burger, M ;
Hartmann, T ;
Burger, JA ;
Schraufstatter, I .
ONCOGENE, 2005, 24 (12) :2067-2075